Skin Cancer

The microRNA member miR-204-5p inhibits apoptosis in melanoma cells treated with dacarbazine or when overexpressed.

Race, ethnicity, years after diagnosis and mental and physical stress are among factors associated with unmet supportive care needs and a higher risk of hospitalization among patients with cancer.

Memory killer cells have been shown to respond to immunotherapy, which is normally administered as a complement to other cancer treatments.

For squamous cell carcinoma systemic therapy that is not concurrent with radiation therapy, preferred regimens are immune checkpoint inhibitors.

Pharmacists can empower their community with essential knowledge for summer skin protection to protect against skin cancer.

Investigators from the Barts Cancer Institute discovered that AMP-activated protein kinase is an essential sensor for tumor dissemination.

The combination also reduced the risk of developing distant metastasis or death by 65% in patients with high-risk stage 3/4 melanoma.

Pediatric drug development, which has a complex background and history, has fundamental catches based around how children are defined in the context of clinical studies.

In the initial cohort, 63% of patients with advanced melanoma achieved an objective response rate, including 6 who had a complete response and 19 who had a partial response to the combination of fianlimab and cemiplimab.

The protozoan intranasal treatment was associated with a strong increase of immune cells within the lung.

Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.

The panel corresponds to proteins that are abundant in treatment-resistant melanoma cells and may predict resistance to targeted treatment.

Study of cell exhaustion in immunotherapy-resistant tumors could significantly improve the benefits of cancer immunotherapy for patients with treatment resistant types of cancer.

Findings may offer insight into new strategies to tackle skin cancer in patients already treated with a prior line of therapy.

The treatment from Keytruda and Merck shows a clinical response of 89% for individuals with unresectable metastatic desmoplastic melanoma.

These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.

Retifanlimab-dlwr (Zynyz; Incyte) was granted FDA accelerated approval for metastatic or recurrent locally advanced Merkel cell carcinoma.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

Nivolumab met its primary endpoint of recurrence-free survival, reducing the risk of recurrence or death by 58% versus placebo in patients with completely resected stage 2B or 2C melanoma.

High-risk areas for disease progression include genitalia and the scalp.

Each therapy presents a different but effective treatment option.

Novel drug development has been focused on the augmentation of the T-lymphocyte response.

Several studies have noted a potential link between methotrexate and an increased risk of skin cancer.

Merck and Moderna’s adjuvant melanoma treatment shows reduced risk of recurrence or death by 44% compared with pembrolizumab alone.

UC Davis cancer researchers hope new technology will help diagnose and treat melanoma more successfully.

Sonidegib binds to and inhibits a transmembrane protein to disrupt hedgehog pathway signal transduction and leading to antitumor activity in patients with locally advanced basal cell carcinoma.

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

KIN-2787 is a potential treatment for BRAF class II or III alteration-positive and/or NRAS mutation-positive, metastatic or unresectable, stage IIB to IV malignant melanoma.

Nivolumab is a biomarker that has been shown to benefit the survival of patients with stage 2 melanoma patients compared with placebo.

New research presented at ESMO Congress found that certain patients with advanced melanoma administered a combination of cemiplimab with fianlimab experienced a median progression-free survival of 2 years.